問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Infectious Disease

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間：2023-09-19

趙文震
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

18Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

趙文震

Taichung Veterans General Hospital

Division of Thoracic Medicine

List

11Cases

2025-10-01 - 2028-12-31

Phase II

Active
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization

  • Condition/Disease

    Bronchiectasis with chronic Pseudomonas aeruginosa infection

  • Test Drug

    Lyophilized powder for injection

Participate Sites
7Sites

Recruiting7Sites

2022-01-01 - 2026-12-31

Phase III

Active
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (TITANIA)

  • Condition/Disease

    Chronic Obstructive Pulmonary Disease

  • Test Drug

    MEDI3506

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites

2023-08-01 - 2028-02-29

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting1Sites

2021-01-04 - 2026-03-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-09-30 - 2026-04-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-07-27 - 2026-09-30

Phase II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
13Sites

Recruiting13Sites

2023-10-16 - 2027-09-09

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2017-06-01 - 2019-12-31

Phase II

Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia

  • Condition/Disease

    Pseudomonas Aeruginosa Pneumonia

  • Test Drug

    Aerucin（aerubumab，AR-105）

Participate Sites
11Sites

Terminated10Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

2021-01-04 - 2023-12-31

Phase III

A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab

  • Condition/Disease

    severe asthmatic participants with an eosinophilic phenotype

  • Test Drug

    GSK3511294

Participate Sites
6Sites

Recruiting1Sites

Terminated5Sites

2022-09-30 - 2025-05-31

Phase III

A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744

  • Condition/Disease

    Asthma

  • Test Drug

    GSK3511294

Participate Sites
9Sites

Recruiting9Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB